On June 12, 2026, Arrowhead Pharmaceuticals appointed Dr. Matt Cohen as a director. Dr. Cohen brings over 25 years of healthcare investing experience, including roles as Managing Director at Vida Ventures and lead growth-focused healthcare investor at JP Morgan Asset Management. In addition to standard non-employee director compensation, he will receive a sign-on grant of restricted stock units valued at $887,000, vesting over three years. The company is a biotechnology firm that develops RNAi therapeutics.